Hidradenitis Suppurativa (HS) Clinical Trial
Official title:
Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis Suppurativa
Verified date | May 2024 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform [ovine forestomach], Hydrofera Blue [methylene blue and gentian violet], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.
Status | Active, not recruiting |
Enrollment | 5 |
Est. completion date | December 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Individuals with hidradenitis suppurativa with non-healing wounds or draining abscesses/nodules - Individuals over 18 years of age Exclusion Criteria: - Individuals younger than 18 years of age - Individuals without a diagnosis of HS |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest Health Sciences Dermatology | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wound Healing Time | Assess the time for wound healing to occur using Endoform and Hydrofera Blue products. | Change from baseline to week 1 | |
Primary | Wound Healing Time | Assess the time for wound healing to occur using Endoform and Hydrofera Blue products. | Change from week 1 to week 2 | |
Primary | Wound Healing Time | Assess the time for wound healing to occur using Endoform and Hydrofera Blue products. | Change from week 2 to week 4 | |
Primary | Wound Healing Time | Assess the time for wound healing to occur using Endoform and Hydrofera Blue products. | Change from week 4 to week 8 | |
Primary | Percent of Wound Healing | Asses the percent healing that occurs over 8 weeks of follow-up using Endoform and Hydrofera Blue products | Measure from Baseline to week 8 | |
Secondary | Pain Assessment | Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain. | Change from baseline to week 1 | |
Secondary | Pain Assessment | Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain. | Change from week1 to week 2 | |
Secondary | Pain Assessment | Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain. | Change from week 2 to week 4 | |
Secondary | Pain Assessment | Assess changes in patient reported pain via Numerical Rating Scale of Pain (NRS) a scale using a number from 0 to 10 where 0 is no pain or hurt and 10 is the most or worst pain. | Change from week 4 to week 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Completed |
NCT02896920 -
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
|
||
Completed |
NCT01468233 -
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT01468207 -
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT03894956 -
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
|
||
Completed |
NCT03001115 -
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
|
||
Not yet recruiting |
NCT05723757 -
Autophagy Dysfunction in Hidradenitis Suppurativa
|
N/A | |
Completed |
NCT02808975 -
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
|
Phase 4 | |
Completed |
NCT04430855 -
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
|
Phase 2 | |
Recruiting |
NCT06212999 -
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 3 | |
Completed |
NCT03487276 -
Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
Recruiting |
NCT05620836 -
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 3 | |
Not yet recruiting |
NCT05735925 -
The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis
|
N/A | |
Recruiting |
NCT05620823 -
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 3 | |
Recruiting |
NCT06241573 -
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
|
Phase 2/Phase 3 | |
Available |
NCT05583604 -
Secukinumab Global MAP Cohort for Adult Patients With Hidradenitis Suppurativa (HS)
|